Insulin's 85th anniversary - An enduring medical miracle

被引:42
作者
Heller, Simon
Kozlovski, Plamen
Kurtzhals, Peter
机构
[1] Univ Sheffield, Royal Hallamshire Hosp, Acad Unit Diabet Endocrinol & Metab, Sheffield S10 2JF, S Yorkshire, England
[2] Novo Nordisk AS, Global Dev, Copenhagen, Denmark
[3] Novo Nordisk AS, Diabet Res, Copenhagen, Denmark
关键词
analogues; delivery; device; insulin;
D O I
10.1016/j.diabres.2007.04.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In 1922, the discovery of insulin led to a revolution in diabetes management. Since then, many improvements have been made to insulin preparations: early preparations of bovine and porcine insulins were purified and their duration of action prolonged, giving rise to the introduction of Neutral Protamine Hagedorn (NPH) insulin and monocomponent insulins. Then, with the advances in genetic engineering in the 1980s, it became possible to produce recombinant human insulin. Nowadays, modem molecular biology techniques enable the production of insulin analogues, which have several advantages over human insulin preparations including a reduced risk of hypoglycaemia. Insulin delivery is still predominantly via subcutaneous injections, but alternative routes of insulin administration are being investigated. Pulmonary delivery has emerged as the most feasible option thus far but oral delivery is an ultimate goal, although basic problems of insulin stability in the gut and absorption from the gastrointestinal tract still need to be resolved. The availability of a true artificial pancreas by means of a closed-loop system, linking continuous glucose monitoring with insulin-pump technology, would also constitute a significant advance, but major technological problems still need to be overcome. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:149 / 158
页数:10
相关论文
共 102 条
[1]  
Ackermann RW, 2006, DIABETOLOGIA, V49, P595
[2]  
Adamson U, 2002, DIABETOLOGIA, V45, pA255
[3]   Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart [J].
Ashwell, S. G. ;
Gebbie, J. ;
Home, P. D. .
DIABETIC MEDICINE, 2006, 23 (08) :879-886
[4]   Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes [J].
Ashwell, SG ;
Amiel, SA ;
Bilous, RW ;
Dashora, U ;
Heller, SR ;
Hepburn, DA ;
Shutler, SD ;
Stephens, JW ;
Home, PD .
DIABETIC MEDICINE, 2006, 23 (03) :285-292
[5]  
*AV PHARM INC, 2005, AP PRESCR INF
[6]  
Banting FG, 1922, J LAB CLIN MED, V7, P251
[7]  
Banting FG, 1922, CAN MED ASSOC J, V7, P141
[8]   Inhaled insulin: a novel route for insulin delivery [J].
Bindra, S ;
Rosenstock, J ;
Cefalu, WT .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (05) :687-691
[9]   THE HISTORY OF INSULIN [J].
BLISS, M .
DIABETES CARE, 1993, 16 :4-7
[10]  
Bliss Michael, 1982, The Discovery of Insulin